Schorge John O, McCann Christopher, Del Carmen Marcela G
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Massachusetts General Hospital, Harvard Medical School Boston, MA.
Rev Obstet Gynecol. 2010 Summer;3(3):111-7.
Three-quarters of women who are newly diagnosed with invasive epithelial ovarian cancer present with stage III to IV disease. Recent data on the efficacy of neoadjuvant chemotherapy have served to challenge the conventional dogma that the preferred initial treatment is surgical debulking. Most of these patients will achieve remission regardless of initial treatment, but 80% to 90% of patients will ultimately relapse. The timing and clinical benefit of a second debulking operation is even more contentious. This article focuses on the recent debate of when or if patients with ovarian cancer should undergo aggressive surgical resection of bulky disease.
新诊断为浸润性上皮性卵巢癌的女性中，四分之三就诊时已处于III至IV期疾病。关于新辅助化疗疗效的最新数据对首选初始治疗为手术减瘤的传统观念提出了挑战。无论初始治疗如何，这些患者中的大多数都能实现缓解，但80%至90%的患者最终会复发。二次减瘤手术的时机和临床获益更具争议性。本文重点关注近期关于卵巢癌患者何时或是否应积极手术切除大块病灶的争论。
